OCT 30·SEC EDGARLow
Atay Oguzhan sold $983K of BLLN
Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at $118.00 ($0.98M total) on 2026-10-28 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · DIAGNOSTICS & RESEARCH
$BLLN
BillionToOne, Inc.
BillionToOne develops molecular diagnostic tests using a single-molecule next-generation sequencing platform to analyze cell-free DNA from blood samples. Its customers include prenatal and oncology clinicians, who use the tests to assess fetal genetic risks, guide cancer therapy selection and monitor treatment response. BillionToOne’s products include the UNITY prenatal testing portfolio, which screens for recessive conditions, aneuploidies and fetal antigens, and the Northstar oncology portfolio, comprising Northstar Select for therapy-selection insights and Northstar Response for tracking tumor burden and response to therapy. BillionToOne makes money by providing diagnostic testing services. Its tests use proprietary Quantitative Counting Templates and sequencing and analytical methods to quantify genetic signals in samples. The company also provides software tools supporting the testing workflow for patients and providers. BillionToOne is headquartered in Menlo Park, California.
Price · $BLLNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BLLN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $6.7M 29 txs
Atay Oguzhan16× · $4.2M
10b5-1 share of filings100%
Top stories · $BLLNMore →
OCT 16·investing.com
BillionToOne CEO Oguzhan Atay sells $1.09 million in stock
BillionToOne CEO Oguzhan Atay sold $1.09M in stock on Oct 14-15, 2026, including direct sales of $829K and indirect sales by his spouse. Shares sold at $98.00-$102.83. BLLN stock is up 24% in six months but down from $102.73. InvestingPro flags it as overvalued. The company has a $4.85B market cap, P/E of 137.73, and 90% revenue growth. Q2 earnings beat expectations with $0.15 EPS and 64% revenue growth. Canaccord Genuity initiated coverage with a $120 target.
OCT 16·SEC EDGAR
Atay Oguzhan sold $829K of BLLN
Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at an average of $99.51 ($98.32–$102.78, $0.83M total) across 7 trades over 2026-10-14 to 2026-10-15 under a Rule 10b5-1 trading plan.
BLLN sentiment & insider activity
Recent BLLN coverage spans insider activity, financial news and technology.
In the last 30 days, BLLN insiders filed 29 SEC Form 4 transactions — no purchases and 29 sales ($6.7M). The most active reporter was Atay Oguzhan, Chairman and CEO, with 16 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving BLLN
The insider sale removes a key executive's ownership, potentially signaling reduced confidence.
Insider selling may weigh on the stock.
The insider sale may signal reduced confidence and could pressure the stock lower.
The insider sale may signal reduced confidence and could pressure the stock lower.
Insider sale of $2.16M may signal negative sentiment for BLLN.
AlphAI scores every news story that mentions BLLN with an AI model for sentiment and relevance, and aggregates insider trades from BillionToOne, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BLLN
Score
Atay Oguzhan sold $983K of BLLN
Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at $118.00 ($0.98M total) on 2026-10-28 under a Rule 10b5-1 trading plan.
1 min readBillionToOne CEO Oguzhan Atay sells $1.09 million in stock
BillionToOne CEO Oguzhan Atay sold $1.09M in stock on Oct 14-15, 2026, including direct sales of $829K and indirect sales by his spouse. Shares sold at $98.00-$102.83. BLLN stock is up 24% in six months but down from $102.73. InvestingPro flags it as overvalued. The company has a $4.85B market cap, P/E of 137.73, and 90% revenue growth. Q2 earnings beat expectations with $0.15 EPS and 64% revenue growth. Canaccord Genuity initiated coverage with a $120 target.
2 min readAtay Oguzhan sold $829K of BLLN
Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at an average of $99.51 ($98.32–$102.78, $0.83M total) across 7 trades over 2026-10-14 to 2026-10-15 under a Rule 10b5-1 trading plan.
1 min readAtay Oguzhan sold $1.6M of BLLN
Atay Oguzhan (Chairman and CEO) sold 16,667 shares of BillionToOne, Inc. (BLLN) at an average of $93.79 ($91.57–$96.39, $1.56M total) across 5 trades on 2026-10-12 under a Rule 10b5-1 trading plan.
1 min readTsao David sold $2.2M of BLLN
Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $108.15 ($105.56–$110.09, $2.16M total) across 11 trades on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min read
BillionToOne, Inc. (BLLN) ctDNA Assay Shows 94% Concordance, Superior in Discordant Cases
BillionToOne (BLLN) reported a peer-reviewed study showing its Northstar Response ctDNA assay had 94% concordance with a tumor-informed test, matching clinical ground truth in all discordant cases. The study supports BLLN's tumor-agnostic monitoring approach, according to the company.
1 min readBillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
BillionToOne (BLLN) announced a peer-reviewed study showing its Northstar Response® liquid biopsy assay performed on par or better than a tumor-informed assay in tracking cancer treatment. The study, published in The Journal of Liquid Biopsy, evaluated 169 samples from 61 patients, finding close alignment in results (R² = 0.97) and agreement in 94% of cases. Northstar Response detected disease progression in cases where the tumor-informed assay did not, highlighting its tumor-agnostic benefits.
2 min readAtay Oguzhan sold $1.0M of BLLN
Atay Oguzhan (Chairman and CEO) sold 8,333 shares of BillionToOne, Inc. (BLLN) at $120.64 ($1.01M total) on 2026-09-28 under a Rule 10b5-1 trading plan.
1 min readLynch Thomas P. sold $3.9M of BLLN
Lynch Thomas P. (See Remarks) sold 35,112 shares of BillionToOne, Inc. (BLLN) at an average of $110.33 ($110.29–$110.36, $3.87M total) across 4 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min read
BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million
BillionToOne (BLLN) CEO Oguzhan Atay sold 30,331 shares for $3M on Sept 14, 2026, per SEC filing. The sale included cash-less option exercises and shares from his spouse's account, executed under a pre-planned trading plan. Atay retains 501,962 vested options and his spouse holds 157,168 shares. BLLN reported $109.4M Q2 2026 revenue, up 64% YoY, and forecasts $450M-$465M for full-year 2026.
2 min read